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Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative approach for patients with a myelodysplastic syndrome (MDS). The incidence of MDS is age-dependent and the vast majority of MDS patients is older than 50 years. For many years, only a small minority of MDS patients qualified for allogeneic HSCT due to procedure-related toxicity after standard total body irradiation or busulfan based conditioning, associated particularly with increasing patient age. During the past years the number of MDS patients who underwent allogeneic HSCT has increased considerably, 1 which might reflect substantial advances in supportive care, but is in particular connected to the development of reduced intensity conditioning (RIC)
regimens. Evaluating the benefit of a particular conditioning regimen in MDS, however, is complicated by the diversity of regimens in use as well as inclusion of patient populations with heterogeneous disease characteristics, like primary and therapy-related MDS or secondary acute myeloid leukemia (AML) arising from MDS, and different prognostic profiles of the patients. Moreover, most of the published studies on conditioning regimens for allogeneic HSCT in MDS patients are retrospective in nature. 2 Reduced intensity conditioning regimens mainly aim at inducing a sufficient immunosuppression to permit engraftment, and rely largely on the graft-versus-malignancy effect for the cure of the patient. Most RIC protocols include fludarabine in combination with reduced doses of either an alkylating agent (e.g., busulfan) or total body irradiation. 2 Compared to standard-dose conditioning, the potential as yet unproven benefit of RIC relies on the reduction of acute regimen-related non-hematologic toxicity and its inherent mortality. With a few exceptions, 3 a major obstacle to successful transplantation after RIC is the higher risk of relapse compared with standard conditioning regimens. 2, 4, 5, [6] [7] [8] Treosulfan is a bifunctional alkylating prodrug with proven myelotoxic and immunosuppressive properties demonstrating high activity toward hematopoietic stem cells. [9] [10] [11] A favorable safety profile in combination with fast and sustained engraftment of treosulfan-based conditioning regimens was demonstrated recently. [12] [13] [14] [15] [16] Low transplantation-related morbidity and sustained engraftment have also been reported in children, even with non-malignant diseases and at high risk for both regimen-related toxicity and graft failure. [17] [18] [19] [20] [21] A doseescalation study in adult patients with a variety of hematologic malignancies qualifying for allogeneic HSCT but with a substantial risk for regimen-related toxicity revealed a treosulfan dose of 3 × 14 g/m² in combination with fludarabine 5 × 30 mg/m² to be a safe and effective conditioning regimen. 22 Based on the available data on low toxicity in combination with myeloablative properties, we consider 'reduced-toxicity conditioning' an appropriate term to characterize this regimen. The current prospective phase II study was designed to investigate the safety and efficacy of this regimen in primary MDS patients with an indication for allogeneic HSCT. Final results of the study are reported after all surviving patients had been observed for one year after transplantation of the last patient included. 
Design and Methods

Patient eligibility
Between November 2004 and July 2007, 45 MDS patients were enrolled in this prospective non-randomized phase II study at 11 study centers in four European countries. Written informed consent on all aspects of the study was obtained from all patients before enrolment. The study was approved by the appropriate independent ethics committees and competent authorities and was performed in accordance with the Declaration of Helsinki.
Patients between 18-65 years of age with MDS according to the World Health Organization (WHO) 2003 classification and an indication for allogeneic HSCT according to institutional policy were included. Patients with therapy-related MDS or AML were not to be included. Detailed eligibility criteria are given in the Online
Supplementary.
Outcome parameters were followed until one year after transplantation of the last patient included.
Donors and grafts
Either HLA-identical siblings or matched unrelated donors were allowed (eight out of eight antigens, Table 1 ).
Serological typing was required for class I (HLA-A/-B) and molecular typing for class II (HLA-DRB1/-DQB1)
antigens.
Conditioning regimen and transplantation
All patients received intravenous (IV) fludarabine 30 mg/m 2 from day -6 to day -2 (total dose: 150 mg/m 2 ) and treosulfan (medac GmbH, Hamburg, Germany) 14 g/m 2 IV on days -6, -5, and -4 (total dose: 42 g/m 2 ) before transplantation. Allogeneic hematopoietic stem cells either from peripheral blood or from bone marrow were given at day 0 (Table 1) .
Supportive care
Graft-versus-host disease (GvHD) prophylaxis consisted of ciclosporin (3 mg/kg/day IV) starting one day before transplantation in combination with short-course methotrexate (15 mg/m 2 IV on day +1 and 10 mg/m 2 IV on days +3 and +6). In case of an unrelated donor, anti-T-cell globulin (ATG-Fresenius (S) ® , Fresenius, Fresenius Biotech, Graefelfing, Germany) was given at a dose of 10 mg/kg IV from day -4 to day -2. Supportive care was done according to center-specific guidelines. The use of human recombinant granulocyte growth factors was not recommended unless clinically indicated.
Engraftment, graft failure and chimerism analysis
Engraftment and graft failure were defined as previously described. 22 Chimerism analysis was performed in the total bone marrow according to established methods of the participating institutions. 
Adverse events
Adverse events including serious adverse events were evaluated from the start of conditioning (day -6) to day +28. In addition, serious adverse events occurring after day +28 had to be reported, if at least a possible relation to the conditioning regimen was suspected. Changes in laboratory values were not included in the adverse event analysis, but were documented separately.
Apart from hepatic veno-occlusive disease (VOD), all adverse events were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE, Version 3.0). Hepatic VOD was evaluated according to standard criteria.
23,24
Assessment of response/relapse
Treatment response and relapse were evaluated according to standard criteria. 25 
Graft-versus-host disease
Graft-versus-host disease (GvHD) was diagnosed and graded according to standard criteria. [26] [27] [28] According to the occurrence of the GvHD episode either before or beyond day +100, GvHD was classified as acute or chronic.
Sample size and statistical considerations
The primary aim of this study was to evaluate the efficacy and safety profile of treosulfan-based conditioning.
With a sample size of 45 patients, an expected neutrophil engraftment rate of 95% could be estimated with a precision of ± 14 percentage points with a power of 80% using a two-sided exact Clopper-Pearson 95% confidence interval. In addition, any toxicity occurring with a probability of at least 5% had a 90% chance of being seen at least once, whereas any toxicity occurring with a probability of 3.5% had an 80% chance of being seen at least once. Time to engraftment was calculated from day 0 by means of conditional cumulative incidence curves. Day +28 rates were extracted there from. Estimates of chimerism, non-relapse mortality (NRM), relapse incidence and acute and chronic GvHD were derived using cumulative incidence rates to accommodate competing risks. Disease-free survival (DFS) and overall survival (OS) were analyzed using product-limit (Kaplan-Meier) estimates. Incidences of selected grade III-IV adverse events reported in the setting of allogeneic HSCT were the primary combined endpoint of the study. The incidence of adverse events was calculated as the number of patients who experienced at least one adverse event of a certain CTCAE category as the percentage of the total number of patients. For exploratory purposes, efficacy data were stratified by type of donor (HLA-identical sibling vs. matched unrelated donor), pre-treatment status (treated vs. untreated), and International Prognostic Scoring System (IPSS) risk score. 29 For the comparison of cumulative incidence curves, the test of Gray was applied, whereas log-rank tests were used for the comparison of product-limit estimates. All p-values were derived from two-sided testing. The statistical analyses were performed using SAS software package V.9.1.3 (SAS Institute, Cary; NC, USA) and R Version 2.2.1 (The R
Foundation for Statistical Computing).
Results
Demographics
A total number of 45 MDS patients were included in the study and treated in line with the study protocol. A single patient with AML was erroneously enrolled but was excluded from the study analysis and was replaced by an additional patient fulfilling the inclusion criteria. Table 1 summarizes the patient and disease characteristics. Only two patients had significant comorbidities as assessed by the treating physician.
Engraftment and chimerism
CTCAE grade IV neutropenia, leukocytopenia and thrombocytopenia occurred in virtually all patients. Table   S1 .
Adverse events
Within the observation period (day -6 to day +28), 39 of 45 patients (87%) experienced at least one episode of grade III-IV adverse events ( Table 2 ). The most frequently reported CTCAE categories were infection (80%) and gastrointestinal (22%). Infections included grade III-IV febrile neutropenia (58%) and infection either with (31%) or without (11%) neutropenia. Gastrointestinal adverse events were mostly of grade III in severity and included nausea (13%) and diarrhea (4%). Only one patient (2%) experienced grade IV mucositis. All other reported grade III-IV adverse events occurred sporadically.
The incidences of selected grade III-IV adverse events reported in the setting of allogeneic HSCT were the primary combined endpoint of the study. Changes in laboratory values were within expected ranges (Online Supplementary Table S2) .
Following day 28 after transplantation, three serious adverse events assessed as at least possibly related to the conditioning regimen were reported. Those were secondary graft failure (starting at day +29), reversible grade III cutaneous ulcerations on both legs secondary to skin necrosis (starting at day +29), and breast cancer (starting at day +685).
Non-relapse mortality
All patients survived the 28-day period after transplantation. Thereafter, seven patients (16 %) died from transplant-related causes. Main causes of death were infections in two patients, and acute or chronic GvHD in one patient each. One patient experienced primary graft failure. Eight days later she developed EBV lymphoproliferative disease leading to fatal multiorgan failure. Another patient experienced secondary graft failure and developed pneumonia complicated by fatal multiorgan failure. One additional patient died at day +52 of multiorgan failure not further specified. The 100-, 360-and 720-day cumulative incidences of NRM were 9%, 13%, and 17%, respectively (Figure 1 ). Non-relapse mortality was similar among patients transplanted from sibling vs. unrelated donors, with IPSS intermediate-1, -2 or high risk, and untreated or chemotherapy pretreated MDS (Online Supplementary Table S3) .
Relapse incidence
Seven patients relapsed during follow-up, resulting in a cumulative incidence of 4% at 100 days, and 16% at 360 and 720 days (Figure 2) . Five of these patients died of relapse. The two-year cumulative incidence of relapse was 20% in patients with sibling compared to 13% in patients with unrelated donor (P = .5665, Gray 
Disease-free survival
The probabilities of DFS were 87% at 100 days, 71% at 360 days, and 67% at 720 days ( Figure 3 ). Patients with sibling donor had a two-year DSF of 57% compared to 73% of the patients with unrelated donor. However, this difference was not significant (P = .4684, log-rank test Figure 3) .
A two-year OS rate of 63% was observed for patients with sibling donor compared to 75% for patients with unrelated donor (P = .5163, log-rank test). In addition, no significant differences were observed among patients within the IPSS groups intermediate-1 (70%), intermediate-2 (68%) and high risk (75%) and for patients with previous chemotherapy (80%) compared to untreated patients (70%; Online Supplementary Table S6) .
Graft-versus-host disease
The day 100 cumulative incidences of grade I-IV, II-IV, and III-IV acute GvHD were 56%, 24%, and 16%, respectively (Online Supplementary Figure S1 ). The cumulative incidence of chronic GvHD at 720 days was 59%, while extensive chronic GvHD reached a cumulative incidence of 28% (Online Supplementary Figure   S2 ).
Discussion
The aim to develop a conditioning regimen consisting of treosulfan and fludarabine was to reduce the incidence and severity of non-hematological acute toxicities frequently observed in allogeneic HSCT recipients after standard conditioning therapy, without compromising the antineoplastic effect. Analyzing the present study results in the context of published data, it is of note that most previous studies included not only patients with primary MDS, but also patients with secondary AML or treatment-related MDS, 30 which may substantially affect study results. As anticipated from previous studies with treosulfan-based conditioning, the acute nonhematologic toxicity of the regimen was low. 12, 15, 16, 22, 31 Hyperbilirubinemia of grade III-IV was noted in 13% of the patients, and only two cases (4%) of moderate VOD were observed. Similarly, the incidence of severe mucositis appears very low when opposed to that usually described for standard conditioning regimens. As can be expected for a standard conditioning regimen, severe infections were common as these are primarily connected to the severity and duration of marrow aplasia. Twenty-two percent of the patients had grade III-IV gastrointestinal symptoms. All other CTCAE grade III-IV toxicities occurred with low frequencies. The incidences and severities of acute and chronic GvHD were in the range of those commonly reported in allogeneic HSCT using standard conditioning regimens. 5, 8, 30, 32 Our GvHD prophylaxis regimen contained three doses of methotrexate. Using the other common version with four doses might have somewhat influenced the incidence of GvHD, and on the other hand the engraftment and possibly the occurrence of adverse effects.
The resulting NRM of 9% at 100 and 17% at 720 days appears similar to that seen after RIC transplantation 5, 7, 8, 30, 33 and lower than those reported after standard conditioning in MDS patients, in which 100-day rates between 19% and 27% have been observed. 5, 30, 34, 35 The prognosis of MDS strongly depends on the subtype of the disease as well as on other prognostic factors. 2, 36 In general, outcome is considered to be more favorable in patients with refractory anemia without blast excess than in those with an excess of blasts. 2, 36, 37, 38, 39 Certain cytogenetic abnormalities and cytopenia in more than one cell line also indicate an adverse prognosis. The IPSS for the estimation of the likelihood of leukemic transformation and survival includes these variables. 29 Our exploratory subgroup analysis revealed no statistically significant influence of the type of donor (sibling or unrelated), IPSS, or previous MDS treatment on relapse incidence, NRM, DFS, or OS. However, the results should be interpreted cautiously due to the small number of patients per subgroup. Recent results of a larger prospective randomized transplantation study showed no prognostic influence of IPSS or blast count on survival while advanced age, number of cytopenias and intermediate to high-risk cytogenetic characteristics were adverse prognostic factors.
40
Comparing favorably to previously published series, 5,33,40 a low and encouraging two-year relapse incidence of only 16% was observed in this study. Thus far, relapse events occurred only within the first 220 days after transplantation. Thereafter, no relapse event has been reported. Using the treosulfan-based conditioning regimen in a prospective allogeneic HSCT protocol, which included several disease entities, rare late disease recurrences have also been noted by Nemecek et al.
31
The two-year estimates of OS and DFS were 71% and 67%, respectively. Approximately one half of fatal events in this study were caused by relapse. These figures appear superior to those published for the results of allogeneic HSCT using standard conditioning regimens 5, 34, 35 and compare favorably to those of some studies using RIC. Ho et al., using fludarabine-busulfan conditioning with 8 mg busulfan/kg, reported one-year OS and DFS rates of 74% and 62%, respectively. However, a considerable proportion of the patients required donor lymphocyte infusion to treat declining donor chimerism. 33 In contrast, Alyea et al., using the same conditioning regimen, reported substantially inferior OS and progression-free survival estimates of 39% and 27% at two years after transplant. 7 Similar results were observed by Shimoni et al. after RIC with fludarabine and intravenous busulfan. Two-year OS and DFS estimates of 47(49)% and 43(49)%, respectively, were reported.
However, that study included also patients with AML, and all MDS patients had excess of blasts. 8 In older AML/MDS patients (> 55 years) similar two-year OS and EFS rates of 46% and 44% have been reported after RIC with fludarabine and intravenous busulfan, and the one-year transplant-related mortality was 19-20%.
41
In preclinical 9, 11, 42 and clinical 12, 16, 22, 31, 43, 44 studies, treosulfan has demonstrated strong cytotoxic activity on hematopoietic cells, while non-hematological toxicity has been generally mild. The present study results are in good accordance with those reports. Owing to prompt engraftment, rapid achievement of full donor hematopoietic chimerism, as well as a comparatively low relapse incidence, the treosulfan/fludarabine conditioning regimen has clearly myeloablative properties, and the term "reduced-toxicity conditioning" appears thus most appropriate for this regimen.
In light of the favorable outcome results with the regimen evaluated in the present study, further investigation of treosulfan and fludarabine conditioning therapy is warranted. A randomized, international Phase III study comparing the treosulfan/fludarabine regimen with a conditioning regimen consisting of reduced-dose busulfan and fludarabine in a large patient cohort stratified by indications AML and MDS is currently under way.
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